A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback